| Literature DB >> 36033259 |
Ya-Nan Wang1, Min Zou2, Dou Wang3, Zhi-Kuan Zhang1, Lian-Ping Qu1, Jing Xu1, Cai-Dong Shi1, Feng Gao2.
Abstract
Objective: This paper aims to explore the relationship between the syndrome differentiation of traditional Chinese medicine (TCM) in colorectal cancer and the clinical laboratory indicators of patients, and to further seek the laboratory indicators to assist TCM syndrome differentiation.Entities:
Keywords: Colorectal cancer; Laboratory indicators; TCM syndrome differentiation
Year: 2022 PMID: 36033259 PMCID: PMC9404354 DOI: 10.1016/j.heliyon.2022.e10207
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Basic data of 122 patients with preoperative colorectal cancer. Note: A shows the gender distribution of 122 patients with preoperative CRC, B shows the distribution of six types of traditional Chinese medicine in 122 patients with preoperative CRC, and C shows the TNM stage distribution of 122 patients with preoperative CRC. Abbreviation:LKYDS:liver-kidney Yin deficiency syndrome. SDQSS:spleen deficiency and Qi stagnation syndrome. SPOS:stasis and poison obstruction syndrome. DHS:damp-heat syndrome. QBDS:Qi and Blood deficiency syndrome. SKYDS:spleen-kidney Yang deficiency syndrome.
Comparison of TCM KPS scores among three groups of colorectal cancer.
| KPS Grade | TCM syndrome | H | ||||
|---|---|---|---|---|---|---|
| Excess syndrome (n = 62) | Deficiency syndrome (n = 29) | Syndrome of intermingled deficiency & excess (n = 31) | ||||
| KPS scores | Grade 1 | 46 (74.19%) | 19 (65.52%) | 14 (45.16%) | 47.752 | <0.001 |
| Grade 2 | 16 (25.81%) | 8 (27.59%) | 17 (54.84%) | |||
| Grade 3 | 0 (0%) | 2 (6.89%) | 0 (0%) | |||
Kruskal-Wallis H test.
Comparison of Clinical features of TCM syndromes among three groups of Colorectal Cancer.
| Clinical features | Clinical classification | Excess syndrome (n = 62) | Deficiency syndrome (n = 29) | Syndrome of intermingled deficiency & excess (n = 31) | |
|---|---|---|---|---|---|
| Gender | Male (%) | 46 (74.19%) | 11 (37.93%) | 17 (54.84%) | 0.003# |
| Female (%) | 16 (25.81%) | 18 (62.07%) | 14 (45.16%) | ||
| Age | 64.56 ± 11.32 | 64.97 ± 14.17 | 65.42 ± 11.90 | 0.888 | |
| Lesion site | Left colon (%) | 9 (14.52%) | 3 (10.34%) | 10 (32.26%) | 0.125 |
| Rectum (%) | 42 (67.74%) | 22 (75.86%) | 19 (61.29%) | ||
| Right colon (%) | 11 (17.74%) | 4 (13.80%) | 2 (6.45%) | ||
| Pathological type | Medium differentiation (%) | 51 (82.26%) | 26 (89.66%) | 27 (87.09%) | 0.521 |
| High differentiation (%) | 7 (11.29%) | 1 (3.44%) | 2 (6,45%) | ||
| Villous adenocarcinoma (%) | 0 (0%) | 0 (0%) | 1 (3.23%) | ||
| Low differentiation (%) | 4 (6.45%) | 2 (6.90%) | 1 (3.23%) | ||
| TNM stage | I (%) | 11 (17.74%) | 4 (13.79%) | 2 (6.45%) | 0.411 |
| II (%) | 25 (40.32%) | 12 (41.39%) | 19 (61.29%) | ||
| III (%) | 22 (35.49%) | 9 (31.03%) | 8 (25.81%) | ||
| IV (%) | 4 (6.45%) | 4 (13.79%) | 2 (6.45%) | ||
| Metastasis | Y (%) | 26 (41.94%) | 13 (44.83%) | 10 (32.26%) | 0.563 |
| N (%) | 36 (58.06%) | 16 (55.17%) | 21 (67.74%) |
#: χ2 test.
Comparison of tumor biomarkers and coagulation index of TCM syndromes among three groups of Colorectal Cancer.
| Clinical features | Excess syndrome | Deficiency syndrome | Syndrome of intermingled deficiency & excess | |
|---|---|---|---|---|
| AFP | 2.50 ± 1.52 | 2.95 ± 1.68 | 2.86 ± 1.38 | 0.347 |
| CEA | 12.95 ± 27.62 | 35.84 ± 109.17 | 5.90 ± 8.00 | 0.621 |
| CA-199 | 303.20 ± 1495.71 | 24.27 ± 60.76 | 21.52 ± 46.68 | 0.521 |
| FIB | 3.14 ± 1.08 | 3.06 ± 0.74 | 3.50 ± 1.48 | 0.410 |
| D-Dimer | 0.69 ± 1.02 | 1.19 ± 2.23 | 0.44 ± 0.48 | 0.554 |
Comparison of the biochemical indicators of TCM syndromes among three groups of Colorectal Cancer.
| Clinical features | Excess syndrome (n = 62) | Deficiency syndrome (n = 29) | Syndrome of intermingled deficiency & excess (n = 31) | |
|---|---|---|---|---|
| AST | 16.21 ± 4.46 | 22.83 ± 26.77 | 16.42 ± 7.92 | 0.647 |
| ALT | 15.56 ± 8.13 | 20.86 ± 25.38 | 16.35 ± 18.94 | 0.498 |
| TP | 63.55 ± 6.60 | 62.46 ± 6.93 | 64.41 ± 4.71 | 0.487 |
| ALB | 37.85 ± 3.34 | 36.34 ± 4.92 | 38.12 ± 3.06 | 0.125 |
| TBIL | 11.24 ± 5.17 | 8.40 ± 3.44 | 9.58 ± 4.39 | 0.023 |
| DBIL | 3.74 ± 1.90 | 3.03 ± 1.15 | 3.01 ± 1.36 | 0.099 |
| ALP | 73.85 ± 21.26 | 75.24 ± 24.63 | 80.41 ± 27.07 | 0.236 |
| GGT | 28.69 ± 28.34 | 30.17 ± 29.83 | 28.65 ± 31.36 | 0.660 |
| UREA | 5.73 ± 1.90 | 6.00 ± 2.69 | 5.77 ± 2.33 | 0.758 |
| CRE | 71.16 ± 14.90 | 65.28 ± 14.34 | 68.23 ± 11.90 | 0.147 |
| UA | 291.60 ± 79.13 | 243.17 ± 53.52 | 270.97 ± 72.60 | 0.013 |
| GFR | 90.22 ± 13.66 | 90.62 ± 13.23 | 90.03 ± 13.57 | 0.782 |
| WBC | 6.05 ± 1.87 | 5.91 ± 2.14 | 6.11 ± 2.12 | 0.657 |
| NEU% | 61.32 ± 11.43 | 60.34 ± 13.04 | 63.70 ± 14.08 | 0.138 |
| RBC | 4.44 ± 0.54 | 4.16 ± 0.60 | 4.38 ± 0.36 | 0.061 |
| HB | 130.80 ± 26.07 | 118.76 ± 21.77 | 126.71 ± 20.18 | 0.043 |
| HCT | 40.66 ± 7.01 | 36.99 ± 6.24 | 39.48 ± 5.06 | 0.041 |
| PLT | 198.68 ± 72.93 | 211.34 ± 71.37 | 216.77 ± 89.31 | 0.537 |
The rank-sum test.
Analysis of variance.
Figure 2Forest Plot for ES vs DS Multivariate Regression Analysis. Abbreviation: ES:Excess Syndrome. DS:Deficiency Syndrome. I: TNM stage I. II: TNM stage II. III: TNM stage III. IV: TNM stage IV. TP: Total protein. RBC: Red blood cell. HB: hemoglobin. HCT: hematocrit. PLT: Platelet. FIB: Fibrinogen.
Figure 3Forest Plot for SIDE vs DS Multivariate Regression Analysis. Abbreviation: SIDE:Syndrome of Intermingled deficiency & excess. DS:Deficiency Syndrome. I: TNM stage I. II: TNM stage II. III: TNM stage III. IV: TNM stage IV. TP: Total protein. RBC: Red blood cell. HB: hemoglobin. HCT: hematocrit. PLT: Platelet. FIB: Fibrinogen.
Figure 4Forest Plot for ES vs SIDE Multivariate Regression Analysis. Abbreviation: ES:Excess Syndrome. SIDE:Syndrome of Intermingled deficiency & excess. I: TNM stage I. II: TNM stage II. III: TNM stage III. IV: TNM stage IV. TP: Total protein. RBC: Red blood cell. HB: hemoglobin. HCT: hematocrit. PLT: Platelet. FIB: Fibrinogen.